Has Sung-Eun Yoo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,274 in general payments to Sung-Eun Yoo, MD across 1,042 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sung-Eun Yoo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sung-Eun Yoo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sung-Eun Yoo, MD

Endocrinology, Diabetes & Metabolism · Cary, NCNPI 1093706103

Payments from drug & device makers

$21,274in general payments, 2019–2025

Across 1,042 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Corcept Therapeutics$3K
Novo Nordisk$2K
Lilly USA, LLC$1K
Abbott$1K
Amgen$924
Radius Health, Inc.$917
plus $11K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Corcept Therapeutics	36	$2,550
Novo Nordisk	167	$2,439
Lilly USA, LLC	101	$1,410
Abbott	83	$1,254
Amgen(2 entities)	53	$924
Radius Health, Inc.	53	$917
AstraZeneca(2 entities)	42	$750
Medtronic(2 entities)	22	$737
Insulet Corporation	20	$584
Boehringer Ingelheim	26	$521
Sanofi-aventis U.S. LLC	31	$519
Esperion Therapeutics, Inc.	25	$499
Xeris Pharmaceuticals, Inc.	21	$489
Senseonics, Incorporated	3	$447
Dexcom, Inc.	24	$425
AbbVie(2 entities)	24	$403
Antares Pharma, Inc.	19	$369
Bayer	16	$368
Ascendis Pharma Endocrinology Inc	11	$333
Mannkind Corporation	17	$333
IBSA Pharma Inc.	18	$316
Vivus LLC	20	$296
BETA Bionics, Inc.	7	$291
Amarin Pharma, Inc.	17	$283
Sequel Med Tech, LLC	3	$273
Tandem Diabetes Care, Inc.	8	$250
Lifescan, Inc.	12	$243
Endo Pharmaceuticals Inc.	13	$229
Amneal Pharmaceuticals LLC	13	$205
Merck	13	$178
Zealand Pharma US, Inc.	9	$169
Novartis	11	$164
Nestle Healthcare Nutrition Inc.	6	$116
Recordati_rare_diseases_inc.	5	$105
Currax Pharmaceuticals LLC	7	$100
Endo USA, Inc.	5	$99
Madrigal Pharmaceuticals	3	$91
Johnson & Johnson(2 entities)	5	$86
Verity Pharmaceuticals Inc.	4	$86
Valeritas, Inc.	5	$83
Takeda Pharmaceuticals U.S.A., Inc.	5	$82
Normatec Industries, LP	1	$75
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$63
Kyowa Kirin, Inc.	3	$63
Embecta Corp.	1	$59
Roche Diabetes Care, Inc.	1	$56
Pfizer	3	$53
Tolmar, Inc.	3	$51
Companion Medical, Inc.	2	$51
Ascensia Diabetes Care US Inc.	2	$50
Shire North American Group Inc	3	$50
Neurocrine Biosciences, Inc.	2	$50
Cequr Corporation	2	$49
Phadia US Inc.	3	$49
Sandoz	3	$47
Rhythm Pharmaceuticals, Inc.	2	$46
Acella Pharmaceuticals, LLC	3	$43
Intra-sana Laboratories	2	$41
Eisai Inc.	2	$38
Ultragenyx Pharmaceutical Inc.	2	$35

How this compares

$21,274 in reported general payments places this provider in the 75th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina →

Medicare billing

Part B allowed, 2024

$1,096,527

Medicare patients

1,163

Services billed

45,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Cary

Khushbu ChandaranaCary$53K
Kathryn LucasMorehead City$37.9M
Mark WarrenGreenville$5M
Mary LawrenceMorehead City$4.9M
John ParkerWilmington$4.1M
John BuseChapel Hill$3.8M
Wendy LaneAsheville$1.9M
Anthony BarberHickory$1.4M
Klara KleinChapel Hill$1.3M
Thomas OconnellBurlington$805K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →